{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"description":"Opportunity cost will be measured through the Oncology Opportunity Cost Assessment Tool (OOCAT) survey.","groups":[{"description":"Patients receive daratumumab and hyaluronidase-fihj SC over 3-5 minutes in the infusion center on day 1 of cycles 1, 2, 7, and 8 and at home on day 1 of cycles 3, 4, 5, and 6. Cycles repeat every 28 days for 8 cycles in the absence of disease progression or unacceptable toxicity.\n\nDaratumumab and Hyaluronidase-fihj: Given SC\n\nQuestionnaire Administration: Ancillary studies\n\nQuality-of-Life Assessment: Ancillary studies\n\nInterview: Ancillary studies","id":"OG000","title":"Treatment (daratumumab and hyaluronidase-fihj)"}],"populationDescription":"Surveys were collected using the Oncology Opportunity Cost Assessment Tool (OOCAT) during the home administration period. However, the data could not be analyzed due to incorrectly completed responses. As a result, no summary statistics or conclusions could be drawn from the opportunity cost data.","reportingStatus":"POSTED","timeFrame":"At Visit 2, Day 29","title":"Opportunity Cost","type":"OTHER_PRE_SPECIFIED"}